Investor Sentiment Declines After Fed Raises Interest Rates By 0.25%

The CNN Money Fear and Greed index showed further decline in overall sentiment among U.S. investors on Wednesday. The Dow Jones closed higher on Wednesday, recording its longest winning streak since 1987 following interest-rate decision from the U.S. Federal Reserve. The index notched gains for the 13th straight session.

The CNN Money Fear and Greed index showed further decline in overall sentiment among U.S. investors on Wednesday.

The Dow Jones closed higher on Wednesday, recording its longest winning streak since 1987 following interest-rate decision from the U.S. Federal Reserve. The index notched gains for the 13th straight session.

The Federal Reserve raised the federal funds rate by 0.25% to 5.25%-5.5% as widely anticipated Wednesday, pushing borrowing costs to their highest level since February 2001.

Alphabet Inc. (NASDAQ:GOOGL) shares gained 5.8% on Wednesday after the company reported better-than-expected second-quarter results. The Boeing Company (NYSE:BA) shares gained 8.7% after the company reported upbeat quarterly results.

The Dow Jones closed higher by around 82 points to 35,520.12 on Wednesday. The S&P 500 fell 0.02% at 4,566.75, while the Nasdaq Composite lost 0.12% at 14,127.28 during the session.

Investors are awaiting earnings results from McDonald’s Corporation (NYSE:MCD), Ford Motor Company (NYSE:F) and Bristol-Myers Squibb Company (NYSE:BMY) today.

At a current reading of 80.0, the index remained in the “Extreme Greed” zone, versus a previous reading of 81.0

What is CNN Business Fear & Greed Index?

The Fear & Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.

 

Read Next: Honeywell Likely To Report Higher Q2 Earnings; Here’s A Look At Recent Price Target Changes By The Most Accurate Analysts

Total
0
Shares
Related Posts
Read More

Why Palisade Bio Stock Is Up Today

Palisade Bio entered into a collaboration with Strand Life Sciences is aimed at advancing precision medicine for ulcerative colitis (UC) therapy and provides the company access to advanced bioinformatics tools vital for understanding complex disease pathways and predicting responses to PDE4 inhibitors. 

PALI

Read More

Cellectis Announces Pricing Of Follow-On $20.2M Public Offering Of 8.8M American Depositary Shares At A Price Of $2.50/ADS; Plans To Use ~$17M Of Proceeds To Fund The Continued Clinical Development Of UCART 123, UCART22, UCART20x22, And UCARTCS1

Cellectis S.A. ("Cellectis" or the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces

CLLS